🔴 BioNTech is trading 9.36% down today despite broader market gains

BioNTech is trading 9.36% down at $100.97, sharply underperforming the broader market, with no clear company-specific catalyst identified.

• The FDA approved updated Pfizer-BioNTech, Moderna, and Novavax-Sanofi COVID-19 vaccines for the 2026–27 season.
• Reliable reports do not identify that announcement as the direct cause of BioNTech’s decline.
• The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average were all modestly higher on August 28, 2026.